Biosceptre announces positive Phase I results for BIL-010t to treat Basal Cell Carcinoma
Cambridge, UK, 23rd July 2014. Biosceptre, the oncology company developing antibody products
Cambridge, UK, 23rd July 2014. Biosceptre, the oncology company developing antibody products
Paper concludes Biosceptre's target nf-P2X7 is ubiquitous to all cancer [...]
Award to develop new therapeutic antibodies targeting nf-P2X7 to treat cancer [...]
Funds to progress Phase I development of oncology product BIL-03s [...]